Get started
Author

Aakanksha Verma

Observed institution: Weizmann Institute of Science
ORCID: 0000-0001-9827-9457
Observed ORCID: 0000-0001-9827-9457
OpenAlex ID: A5006090403
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2022 · Ashish Noronha, Nishanth Belugali Nataraj, et al. · Cancer Discovery · 109
PDF
TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications
2025 · Arunachalam Sekar, Rishita Chatterjee, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al. · 1
TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens
2026 · Arunachalam Sekar, Boobash Raj Selvadurai, et al. · EMBO Molecular Medicine
PDF
Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Figure from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Supplementary Data from AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2023 · Ashish Noronha, Nishanth Belugali Nataraj, et al.
Works count: 13
Citation count: 111
H-index: 1
I10-index: 1
Year
Topic
Type